Kaken Pharmaceutical <4521.T>-2007/08 parent

May 12 (Reuters) -

KAKEN PHARMACEUTICAL CO LTD

PARENT-ONLY FINANCIAL HIGHLIGHTS

(in billions of yen unless specified)

Year ended Year ended Year to Six months to

Mar 31, 2008 Mar 31, 2007 Mar 31, 2009 Sep 30, 2008

LATEST YEAR-AGO COMPANY COMPANY

RESULTS RESULTS FORECASTS H1 FORECASTS
Sales 78.20 74.59 82.80 40.40

(+4.8 pct) (+0.8 pct) (+3.6%) (+2.2%)
Operating 9.22 7.54 10.20 5.30

(+22.3 pct) (-3.1 pct) (+3.6%) (-0.7%)
Recurring 8.85 7.26 9.70 5.00

(+22.0 pct) (+1.5 pct) (+3.7%) (-1.8%)
Net 4.82 4.39 5.60 2.90

(+9.8 pct) (+19.2 pct) (+9.7%) (+2.7%)
EPS Y45.60 Y40.44 Y55.27 Y28.62
Diluted
EPS Y45.38 Y38.92
Annual div Y20.00 Y17.00 Y23.00
-Q2 div Y10.00 Y8.50 Y11.50
-Q4 div Y10.00 Y8.50 Y11.50

NOTE - Kaken Pharmaceutical Co Ltd specialises in drugs for practitioners.

If there is no Q1 or Q3 dividend, Q2 will in most cases
correspond to the first-half dividend and Q4 to the second-half
dividend announced before a new corporate law in 2006 allowed
companies to pay and report dividends on a quarterly basis.

For latest earnings estimates made by Toyo Keizai, please
double click on 4521.TK1.